PMID- 30928971
OWN - NLM
STAT- MEDLINE
DCOM- 20191209
LR  - 20191217
IS  - 1421-9832 (Electronic)
IS  - 1018-8665 (Linking)
VI  - 235
IP  - 3
DP  - 2019
TI  - Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a 
      Multicenter Experience.
PG  - 213-218
LID - 10.1159/000497274 [doi]
AB  - BACKGROUND: Switching between biologics is commonly performed for the management 
      of plaque psoriasis. However, no evidence about switching from secukinumab to 
      ustekinumab has been reported. METHODS: This retrospective observational 
      multicenter study aimed to describe efficacy and safety of ustekinumab in 
      secukinumab nonresponder patients. RESULTS: A total of 21 patients unresponsive 
      to secukinumab were treated with ustekinumab for a mean period of 53.3 weeks. 
      Ustekinumab was effective in reducing disease severity, with significant 
      improvements of both psoriasis area severity index (PASI) and dermatology quality 
      of life index (DLQI) scores. PASI score improvements of 31.8, 44, 77.8, 80.3, 
      80.5, and 89.6%, at week 4, 12, 24, 36, 48, and above 60 weeks, respectively, 
      were detected (p < 0.05), achieving PASI 50, 75, and > 90 responses in 93.8, 
      87.5, and 50% of patients at week 48. Four patients withdrew from ustekinumab 
      treatment because of inefficacy, and failure of multiple biologic agents (> 2) 
      seemed to affect ustekinumab drug survival. No serious adverse events (AEs) were 
      reported while 38.1% of patients experienced mild AEs. CONCLUSION: Ustekinumab 
      was safe and effective in treating patients unresponsive to secukinumab.
CI  - (c) 2019 S. Karger AG, Basel.
FAU - Chiricozzi, Andrea
AU  - Chiricozzi A
AD  - Institute of Dermatology, Catholic University - Fondazione Policlinico 
      Universitario A. Gemelli IRCCS, Rome, Italy, chiricozziandrea@gmail.com.
AD  - Dermatology Unit, Department of Clinical and Experimental Medicine, University of 
      Pisa, Pisa, Italy, chiricozziandrea@gmail.com.
FAU - Conti, Andrea
AU  - Conti A
AD  - Department of Head and Neck Surgery, Section of Dermatology, Azienda Ospedaliero 
      Universitaria Policlinico di Modena, Modena, Italy.
FAU - Burlando, Martina
AU  - Burlando M
AD  - Section of Dermatology, University of Genoa, Di.S.Sal., San Martino Policlinic 
      Hospital, Genoa, Italy.
FAU - Odorici, Giulia
AU  - Odorici G
AD  - Department of Head and Neck Surgery, Section of Dermatology, Azienda Ospedaliero 
      Universitaria Policlinico di Modena, Modena, Italy.
FAU - Gaiani, Francesca
AU  - Gaiani F
AD  - Dermatology Unit, Azienda Ospedaliera San Donato Milanese, Milan, Italy.
FAU - Panduri, Salvatore
AU  - Panduri S
AD  - Dermatology Unit, Department of Clinical and Experimental Medicine, University of 
      Pisa, Pisa, Italy.
FAU - Malagoli, Piergiorgio
AU  - Malagoli P
AD  - Dermatology Unit, Azienda Ospedaliera San Donato Milanese, Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20190329
PL  - Switzerland
TA  - Dermatology
JT  - Dermatology (Basel, Switzerland)
JID - 9203244
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biological Products)
RN  - DLG4EML025 (secukinumab)
RN  - FU77B4U5Z0 (Ustekinumab)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Biological Products/*therapeutic use
MH  - Cohort Studies
MH  - *Drug Substitution
MH  - Female
MH  - Humans
MH  - Italy
MH  - Male
MH  - Middle Aged
MH  - *Patient Safety
MH  - Prognosis
MH  - Psoriasis/*drug therapy/pathology/psychology
MH  - Quality of Life
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Severity of Illness Index
MH  - Sex Factors
MH  - Treatment Outcome
MH  - Ustekinumab/*therapeutic use
MH  - Young Adult
OTO - NOTNLM
OT  - Psoriasis
OT  - Secukinumab
OT  - Switch
OT  - Ustekinumab
EDAT- 2019/04/01 06:00
MHDA- 2019/12/18 06:00
CRDT- 2019/04/01 06:00
PHST- 2018/09/24 00:00 [received]
PHST- 2019/01/25 00:00 [accepted]
PHST- 2019/04/01 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
PHST- 2019/04/01 06:00 [entrez]
AID - 000497274 [pii]
AID - 10.1159/000497274 [doi]
PST - ppublish
SO  - Dermatology. 2019;235(3):213-218. doi: 10.1159/000497274. Epub 2019 Mar 29.